Kodiak’s stock rallies on Phase III wAMD success

If approved by regulators, Kodiak's Zenkuda will compete with blockbuster drugs like Eylea and Vabysmo on the wAMD market. If approved, Zenkuda will compete with blockbuster wAMD sellers like Eylea and Vabysmo. Kodiak will file for Zenkuda’s approval in wAMD following these positive results. Credit: recep kart / Shutterstock.com. Kodiak Sciences’ stock has soared by upwards of 90% after securing a duo of late-stage wins for its ophthalmology candidates, Zenkuda (tarcocimab tedromer) and tabirafusp-ted, in wet age-related macular degeneration (wAMD) – leading the company to tee up a potential approval for the former drug. During the triple-arm Phase III DAYBREAK…

Source: Clinical Trials Arena